Lead Sponsor

Novartis Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. patients currrently participating in Novartis study CAMN107A2109
•2. imatinib - resistant or intolerant - Philadelphia chromosome-positive CML in chronic (CML-CP)accelerated phase (CML-AP) or in blast crisis (CML-BC)
•3. males or females ≥18 years of age
•4. WHO Performance Status of ≤ 2
•5. patients must have the following laboratory values: ALT and AST ≤ 2.5 x ULN or ≤ 5.0 x ULN if considered due to tumor

•1. Impaired cardiac function; use of therapeutic coumarin derivatives
•2. patients who have undergone a major surgery and have not recovered from side effects of such therapy within 15 days
•3. patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control
•4. patients who have received chemotherapy ≤ 1 week or who are within 5 half-lives of their last dose of chemotherapy
•5. ,.patients who have received imatinib or dasatinib at least 3 days prior to beginning of study drug or who have not recovered from side effects of such therapy

Related studies

NCT06514534 · Chronic Myeloid Leukemia (CML)

NCT05143840 · Chronic Myeloid Leukemia, Chronic Phase, Adult CML, and more

NCT06994676 · High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), and more

NCT06523556 · Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and more

NCT06236724 · Chronic Myeloid Leukemia

Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase